PEP-010 has received orphan drug designation for pancreatic cancer, emphasizing the need for novel treatments in this high-mortality disease. The peptide disrupts Caspase-9 and PP2A interaction, ...
The FDA granted an orphan drug designation to PEP-010 for the treatment of patients with metastatic pancreatic cancer.
PEP-Therapy receives FDA Orphan Drug Designation for PEP-010 for treatment of Pancreatic Cancer Paris (France), March 17, 2025 – PEP-Therapy, a clinical-stage biotechnology company developing ...
“Obtaining Orphan Drug Designation for PEP-010 marks a significant milestone in our efforts to develop our drug candidate for pancreatic cancer and highlights the significant unmet medical need ...
"Obtaining Orphan Drug Designation for PEP-010 marks a significant milestone in our efforts to develop our drug candidate for pancreatic cancer and highlights the significant unmet medical need that ...